Inclusion Criteria:

- Pregnant; women identified at any trimester of pregnancy may enroll in this study as
long as enrollment occurs prior to experiencing pregnancy outcome

- Exposure to at least one dose of Herceptin (as adjuvant or metastatic treatment) or
Perjeta plus Herceptin combination treatment during pregnancy or within 6 months
prior to conception

- United States resident

- Patient has provided verbal or written informed consent (on her own behalf and on
behalf of her child)

Exclusion Criteria:

- Prior knowledge of pregnancy outcome at time of enrollment